Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

fmc australasia pty ltd - copper (cu) present as cupric hydroxide - dry flowable - copper (cu) present as cupric hydroxide mineral-copper active 400.0 g/kg - fungicide - almond | apple | apricot | avocado | banana | bean | brassica vegetables | capsicum or pepper | carrot | celery | cherry | citru - algae | alternaria leaf spot - alternaria spp. | angular leaf spot on cucurbit | angular leaf spot-p. syringae pv. tabaci | anthracnose - colletotrichum spp. | anthracnose - marssonina panattoniana | anthracnose on pawpaw, mango or avocado | ascochyta blight | bacterial black spot | bacterial brown spot | bacterial canker - c. michiganense | bacterial gummosis | bacterial leaf spot | bacterial leaf spot - x. campestris | bacterial leaf spot on lettuce | bacterial speck | bacterial spot | bacterial spot on tomato | black rot on cole crop/brassica | black spot - guignardia citricarpa | black spot on pears | black spot/scab in apple/pear | cercospora leaf spot | cercospora leaf spot - banana | chocolate spot on bean | citrus melanose | citrus scab | common blight | crown top rot | downy mildew - peronospora farinosa | downy mildew on allium (onion, garlic) | downy mildew on cole crop/brassica | downy mildew on grape | downy mildew on lettuce | downy mildew on rhubarb | early blight or target blackspot | freckle

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

accensi pty ltd - copper present as copper oxychloride - wettable powder - copper present as copper oxychloride mineral-copper active 500.0 g/kg - fungicide - almond | apple | apricot | avocado | banana | blackcurrant | brassica vegetables | capsicum or pepper | carrot | celery | cherry - algae | algal leaf spot | angular leaf spot on cucurbit | angular leaf spot-p. syringae pv. tabaci | anthracnose | anthracnose husk rot | anthracnose on guava | anthracnose on pawpaw, mango or avocado | anthracnose or ring spot on lettuce | ascochyta blight | bacterial black spot | bacterial blight | bacterial blight wilt | bacterial canker - c. michiganense | bacterial canker on tomato | bacterial gummosis | bacterial leaf spot on lettuce | bacterial speck | bacterial spot on capsicum | bacterial spot on cucurbit | bacterial spot on tomato | black spot | black spot on apples | black spot on citrus | black spot on pears | brown spot on passionfruit | cercospora leaf spot - banana | citrus melanose | citrus scab | crown rot | downy mildew | downy mildew - peronospora farinosa | downy mildew on cole crop/brassica | downy mildew on lettuce | downy mildew on ornamentals | downy mildew on rhubarb | early blight (target spot) | early blight on celery | freckle or scab on stone fruit | fungus | husk spot - cercosept

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

grochem australia pty ltd - copper present as copper oxychloride - water dispersible granule - copper present as copper oxychloride mineral-copper active 500.0 g/kg - fungicide - almond | apricot | avocado | banana | blackcurrant | brassica vegetables | capsicum or pepper | carnation | carrot | celery | ci - algae | algal leaf spot | alternaria leaf blight or spot blight | alternaria leaf spot - alternaria spp. | angular leaf spot on cucurbit | anthracnose | anthracnose husk rot | anthracnose on guava | anthracnose on pawpaw, mango or avocado | anthracnose or ring spot on lettuce | ascochyta blight | bacterial black spot | bacterial blight | bacterial brown spot | bacterial canker - c. michiganense | bacterial canker - c. michiganensis | bacterial canker on stone fruit | bacterial gummosis | bacterial leaf spot | bacterial leaf spot - x. campestris | bacterial leaf spot on lettuce | bacterial speck | bacterial spot - x. campestris pv. pruni | bacterial spot - xanthomonas vesicatoria | bacterial spot on tomato | bitter rot | black rot on cole crop/brassica | black spot - guignardia citricarpa | black spot - venturia spp. | black spot on grapes - elsinoe ampelina | black spot on rose - diplocarpon rosae | blossom blight - monilinia laxa | brown rot - phytophthora citrophthora | brown spot on mandarin | brown spot o

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

liquid fertiliser pty ltd - copper (cu) present as cupric hydroxide - suspension concentrate - copper (cu) present as cupric hydroxide mineral-copper active 50.0 g/l - fungicide - almond | apple | apricot | avocado | banana | bean | brassica spp. or cole crop | capsicum or pepper | carrot | celery | cherry - algae | algal spot | angular leaf spot on cucurbit | angular leaf spot-p. syringae pv. tabaci | anthracnose on pawpaw, mango or avocado | anthracnose or ring spot on lettuce | ascochyta blight | bacterial brown spot | bacterial canker - c. michiganense | bacterial gummosis | bacterial leaf spot - p. andropogonis | bacterial leaf spot - x. campestris | bacterial leaf spot on lettuce | bacterial speck | bacterial spot on tomato | black rot on cole crop/brassica | black spot - guignardia citricarpa | black spot on apples | black spot on pears | botrytis | cercospora leaf spot - banana | citrus melanose | citrus scab | common blight | crown top rot | downy mildew | downy mildew - peronospora farinosa | downy mildew on allium (onion, garlic) | downy mildew on cole crop/brassica | downy mildew on grape | downy mildew on lettuce | downy mildew on rhubarb | early blight or target blackspot | freckle or scab on stone fruit | halo blight | late or irish blight on tomato or potato | leaf curl | leaf spot - alternaria ce

Israel - English - Ministry of Health

novartis israel ltd - ruxolitinib as phosphate - tablets - ruxolitinib as phosphate 5 mg - ruxolitinib - ruxolitinib - * * myelofibrosis (mf) jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. * polycythaemia vera (pv) jakavi is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.*graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies

Israel - English - Ministry of Health

novartis israel ltd - ruxolitinib as phosphate - tablets - ruxolitinib as phosphate 15 mg - ruxolitinib - ruxolitinib - * myelofibrosis (mf) jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. * polycythaemia vera (pv) jakavi is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.*graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies

Israel - English - Ministry of Health

novartis israel ltd - ruxolitinib as phosphate - tablets - ruxolitinib as phosphate 20 mg - ruxolitinib - ruxolitinib - * myelofibrosis (mf) jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. * polycythaemia vera (pv) jakavi is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.*graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nufarm australia limited - copper (cu) present as cupric hydroxide - water dispersible granule - copper (cu) present as cupric hydroxide mineral-copper active 500.0 g/kg - fungicide

European Union - English - EMA (European Medicines Agency)

sandoz gmbh - rituximab - lymphoma, non-hodgkin; arthritis, rheumatoid; leukemia, lymphocytic, chronic, b-cell; wegener granulomatosis; microscopic polyangiitis; pemphigus - antineoplastic agents - rixathon is indicated in adults for the following indications:non-hodgkin’s lymphoma (nhl)rixathon is indicated for the treatment of previously untreated adult patients with stage iii-iv follicular lymphoma in combination with chemotherapy.rixathon maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy.rixathon monotherapy is indicated for treatment of adult patients with stage iii-iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy.rixathon is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.rixathon in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll).chronic lymphocytic leukaemia (cll)rixathon in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including rituximab or patients refractory to previous rituximab plus chemotherapy.see section 5.1 for further information.rheumatoid arthritisrixathon in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease modifying anti-rheumatic drugs (dmard) including one or more tumour necrosis factor (tnf) inhibitor therapies.rituximab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with methotrexate.granulomatosis with polyangiitis and microscopic polyangiitisrixathon, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa).rixathon, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active gpa (wegener’s) and mpa.pemphigus vulgarisrixathon is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).

European Union - English - EMA (European Medicines Agency)

sandoz gmbh - rituximab - lymphoma, non-hodgkin; arthritis, rheumatoid; microscopic polyangiitis; wegener granulomatosis - antineoplastic agents - riximyo is indicated in adults for the following indications:non-hodgkin’s lymphoma (nhl)riximyo is indicated for the treatment of previously untreated adult patients with stage iii-iv follicular lymphoma in combination with chemotherapy.riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy.riximyo monotherapy is indicated for treatment of adult patients with stage iii-iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy.riximyo is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll).chronic lymphocytic leukaemia (cll)riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including rituximab or patients refractory to previous rituximab plus chemotherapy.see section 5.1 for further information.rheumatoid arthritisriximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (dmard) including one or more tumour necrosis factor (tnf) inhibitor therapies.rituximab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with methotrexate.granulomatosis with polyangiitis and microscopic polyangiitisriximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa).riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active gpa (wegener’s) and mpa.pemphigus vulgarisriximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).